Martin Landray
{{short description|British epidemiologist and professor (born c. 1968)}}
{{Infobox scientist
| honorific_prefix = Sir
| name = Martin Landray
| birth_date = {{circa|{{birth year and age|1968}}}}
| birth_place =
| death_date =
| death_place =
| honorific_suffix =
| alma_mater = Abingdon School
University of Birmingham
| workplaces = University of Oxford
| website = {{URL|https://www.bdi.ox.ac.uk/Team/martin-landray}}
}}
Sir Martin Jonathan Landray (born {{circa|1968}}) is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals.{{cite web |title=Why the UK is ahead of the curve in the global race to find coronavirus treatments - Q&A with Martin Landray |url=https://reaction.life/why-the-uk-is-ahead-of-the-curve-in-the-global-race-to-find-coronavirus-treatments-qa-with-martin-landray/ |website=Reaction |date=22 April 2020}} Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.{{cite news |title=The challenge of saving lives with 'big data' |url=https://www.bbc.co.uk/news/health-35491177 |access-date=16 October 2020 |work=BBC News |date=7 February 2016}}
Early life and education
Landray was born the son of a general practitioner, Bob Landray and an anaesthetist, Margaret Bray.{{cite web |url=https://atom.bamptonarchive.org/index.php/the-landray-family-a-family-of-doctors |title=The Landry Family |website=Bampton Archives |access-date=14 June 2021}} He was educated at Abingdon School in Abingdon-on-Thames, Oxfordshire, from 1982 until 1987. He was a prefect and played rugby and cricket.{{cite web|url=https://www.abingdon.org.uk/uploads/school/files/abingdonian/1987_December_V018_N005.pdf#page=7|title=Prefects|website=The Abingdonian|access-date=14 June 2021}}{{cite web|url=https://www.abingdon.org.uk/uploads/school/files/abingdonian/1986_December_V018_N004.pdf#page=23|title=Music report|website=The Abingdonian|access-date=14 June 2021}} After Abingdon he went on to study medicine at the University of Birmingham, returning later for specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine.{{cite web|url=https://www.ndph.ox.ac.uk/team/martin-landray|title=Martin Landray|website=Nuffield Department of Population Health|access-date=14 June 2021}}
Career
Landray serves as co-chief investigator of the RECOVERY Trial into treatment drugs for COVID-19 (the largest such clinical trial in the world) alongside Peter Horby.{{Cite web|title=ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)|url=http://www.isrctn.com/ISRCTN50189673|access-date=2020-09-06|website=www.isrctn.com|language=en}}{{cite web |title=Large-scale trial for coronavirus drugs launches in UK |url=https://www.clinicaltrialsarena.com/news/coronavirus-trial-uk-treatments/ |website=Clinical Trials Arena |access-date=7 September 2020 |date=6 April 2020}}{{cite web |title=Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences |url=https://www.ndorms.ox.ac.uk/news/managing-clinical-trials-during-the-pandemic |website=www.ndorms.ox.ac.uk |access-date=7 September 2020}} In June 2020, the trial discovered the first known life-saving COVID-19 drug, Dexamethasone.{{Cite web|title=Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 {{!}} University of Oxford|url=https://www.ox.ac.uk/news/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe|access-date=2020-09-06|website=www.ox.ac.uk}}{{Cite web|title=Prime Minister's statement on coronavirus (COVID-19): 16 June 2020|url=https://www.gov.uk/government/speeches/pm-statement-at-the-coronavirus-press-conference-16-june-2020|access-date=2020-09-06|website=GOV.UK|date=16 June 2020 |language=en}}{{cite journal | vauthors = Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ | display-authors = 6 | title = Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report | journal = The New England Journal of Medicine | date = July 2020 | volume = 384 | issue = 8 | pages = 693–704 | pmid = 32678530 | pmc = 7383595 | doi = 10.1056/NEJMoa2021436 }} The trial also showed that Tocilizumab further reduces the risk of death for the sickest patients with COVID-19.{{cite journal |title=RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |year=2021|pmid=33933206|author1=RECOVERY Collaborative Group|journal=Lancet|volume=397|issue=10285|pages=1637–1645|doi=10.1016/S0140-6736(21)00676-0 |issn=0140-6736 |pmc=8084355}} The trial found that a number of other treatments had no meaningful benefits for patients hospitalised with COVID-19, including Hydroxychloroquine,{{cite journal |last1=Group |first1=The RECOVERY Collaborative |title=Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 |journal=New England Journal of Medicine |date=8 October 2020 |volume=383 |issue=21 |pages=2030–2040 |doi=10.1056/NEJMoa2022926 |pmid=33031652 |pmc=7556338 |url=|language=en}} Lopinavir/ritonavir,{{cite journal |last1=Horby |first1=Peter W. |last2=Mafham |first2=Marion |last3=Bell |first3=Jennifer L. |last4=Linsell |first4=Louise |last5=Staplin |first5=Natalie |last6=Emberson |first6=Jonathan |last7=Palfreeman |first7=Adrian |last8=Raw |first8=Jason |last9=Elmahi |first9=Einas |last10=Prudon |first10=Benjamin |last11=Green |first11=Christopher |last12=Carley |first12=Simon |last13=Chadwick |first13=David |last14=Davies |first14=Matthew |last15=Wise |first15=Matthew P. |last16=Baillie |first16=J. Kenneth |last17=Chappell |first17=Lucy C. |last18=Faust |first18=Saul N. |last19=Jaki |first19=Thomas |last20=Jefferey |first20=Katie |last21=Lim |first21=Wei Shen |last22=Montgomery |first22=Alan |last23=Rowan |first23=Kathryn |last24=Juszczak |first24=Edmund |last25=Haynes |first25=Richard |last26=Landray |first26=Martin J. |title=Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |journal=The Lancet |date=5 October 2020 |volume=396 |issue=10259 |pages=1345–1352 |doi=10.1016/S0140-6736(20)32013-4 |pmid=33031764 |pmc=7535623 |url=|language=English |issn=0140-6736}} Azithromycin,{{cite journal |title=Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |year=2021|pmid=33545096|author1=RECOVERY Collaborative Group|journal=Lancet|volume=397|issue=10274|pages=605–612|doi=10.1016/S0140-6736(21)00149-5|pmc=7884931}} Convalescent plasma,{{cite journal |title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial |year=2021|doi=10.1016/S0140-6736(21)00897-7|last1=Horby|first1=Peter W.|last2=Estcourt|first2=Lise|last3=Peto|first3=Leon|last4=Emberson|first4=Jonathan R.|last5=Staplin|first5=Natalie|last6=Spata|first6=Enti|last7=Pessoa-Amorim|first7=Guilherme|last8=Campbell|first8=Mark|last9=Roddick|first9=Alistair|last10=Brunskill|first10=Nigel E.|last11=George|first11=Tina|last12=Zehnder|first12=Daniel|last13=Tiberi|first13=Simon|last14=Aung|first14=Ni Ni|last15=Uriel|first15=Alison|last16=Widdrington|first16=John|last17=Koshy|first17=George|last18=Brown|first18=Thomas|last19=Scott|first19=Steven|last20=Baillie|first20=J Kenneth|last21=Buch|first21=Maya H.|last22=Chappell|first22=Lucy C.|last23=Day|first23=Jeremy N.|last24=Faust|first24=Saul N.|last25=Jaki|first25=Thomas|last26=Jeffery|first26=Katie|last27=Juszczak|first27=Edmund|last28=Lim|first28=Wei Shen|last29=Montgomery|first29=Alan|last30=Mumford|first30=Andrew|journal=Lancet|volume=397|issue=10289|pages=2049–2059|pmid=34000257|pmc=8121538|display-authors=1|hdl=10044/1/90411|s2cid=232168245|url=https://ora.ox.ac.uk/objects/uuid:1938e64d-23a8-4093-8f7c-0851a8bede7a|hdl-access=free}} and Colchicine.{{Cite web|url=https://www.recoverytrial.net/news/recovery-trial-closes-recruitment-to-colchicine-treatment-for-patients-hospitalised-with-covid-19|title=RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19 — RECOVERY Trial}} The trial continues to study REGN-COV2 and Baricitinib.{{cite web |title=Welcome — RECOVERY Trial |url=https://www.recoverytrial.net/ |website=www.recoverytrial.net |access-date=16 October 2020}}
He leads the Good Clinical Trials Collaborative, established by Wellcome Trust, Bill & Melinda Gates Foundation, and African Academy of Sciences which seeks to develop and promote the adoption of new international guidelines for randomised control trials. He was previously one of the leaders of the Clinical Trial Transformation Initiative's{{cite web |url=https://www.ctti-clinicaltrials.org/ |title=Home |website=ctti-clinicaltrials.org}} risk-based monitoring,{{Cite web |url=https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf |title=Archived copy |access-date=2021-05-03 |archive-date=2021-05-03 |archive-url=https://web.archive.org/web/20210503154411/https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/recommendations/monitoring-recommendations.pdf |url-status=dead }} quality-by-design,{{cite web |url=https://www.ctti-clinicaltrials.org/projects/quality-design |title=Quality by Design {{!}} Clinical Trials Transformation Initiative |website=www.ctti-clinicaltrials.org |url-status=dead |archive-url=https://web.archive.org/web/20170327092841/https://www.ctti-clinicaltrials.org/projects/quality-design |archive-date=2017-03-27}} and mobile clinical trial projects.{{cite news |last1=Entis |first1=Laura |title=Can smartphone drug trials improve medical care? |url=https://www.theguardian.com/lifeandstyle/2016/jan/27/smartphone-mobile-drug-trials-fda-pfizer-ctti-depression-us-health |access-date=16 October 2020 |work=The Guardian |date=27 January 2016}} He is an advocate of streamlined approaches to clinical trial design, delivery and regulation as a means to improve healthcare.{{cite journal |title=Improving public health by improving clinical trial guidelines and their application |year=2017|pmid=28329235|last1=Landray|first1=M. J.|last2=Bax|first2=J. J.|last3=Alliot|first3=L.|last4=Buyse|first4=M.|last5=Cohen|first5=A.|last6=Collins|first6=R.|last7=Hindricks|first7=G.|last8=James|first8=S. K.|last9=Lane|first9=S.|last10=Maggioni|first10=A. P.|last11=Meeker-o'Connell|first11=A.|last12=Olsson|first12=G.|last13=Pocock|first13=S. J.|last14=Rawlins|first14=M.|last15=Sellors|first15=J.|last16=Shinagawa|first16=K.|last17=Sipido|first17=K. R.|last18=Smeeth|first18=L.|last19=Stephens|first19=R.|last20=Stewart|first20=M. W.|last21=Stough|first21=W. G.|last22=Sweeney|first22=F.|last23=Van De Werf|first23=F.|last24=Woods|first24=K.|last25=Casadei|first25=B.|journal=European Heart Journal|volume=38|issue=21|pages=1632–1637|doi=10.1093/eurheartj/ehx086|pmc=5837481}}{{cite journal |title=The Magic of Randomization versus the Myth of Real-World Evidence |year=2020|pmid=32053307|last1=Collins|first1=R.|last2=Bowman|first2=L.|last3=Landray|first3=M.|last4=Peto|first4=R.|journal=The New England Journal of Medicine|volume=382|issue=7|pages=674–678|doi=10.1056/NEJMsb1901642|s2cid=211100475}} He is founding director and chair of NHS DigiTrials,{{Cite web|url=https://digital.nhs.uk/services/nhs-digitrials|title = NHS DigiTrials}} the Health Data Research Hub for Clinical Trials hosted by NHS Digital, and leads the clinical trials theme for Health Data Research UK.{{Cite web|url=https://www.hdruk.ac.uk/using-health-data/clinical-trials/|title = Clinical Trials}}
In 2021, Landray was appointed to the Pandemic Preparedness Partnership (PPP), a group chaired by Patrick Vallance to advise the G7 presidency held by the government of Prime Minister Boris Johnson.[https://www.gov.uk/government/news/new-global-partnership-launched-to-fight-future-pandemics New global partnership launched to fight future pandemics ] Government of the United Kingdom, press release of April 20, 2021.
He was knighted in the 2021 Birthday Honours for services to public health and science.{{London Gazette|issue=63377|supp=y|page=B2|date=12 June 2021}}
Positions held
Landray holds the following positions:{{cite web |title=Martin Landray — Nuffield Department of Population Health |url=https://www.ndph.ox.ac.uk/team/martin-landray |website=www.ndph.ox.ac.uk |access-date=16 October 2020}}
- Professor of Medicine & Epidemiology, Nuffield Department of Population Health, University of Oxford{{cite web |url=https://www.ndph.ox.ac.uk/ |title=Home |website=ndph.ox.ac.uk}}
- Deputy Director, Big Data Institute, University of Oxford{{cite web |url=https://www.bdi.ox.ac.uk/ |title=Home |website=bdi.ox.ac.uk}}
- Lead, Big Data & Computing Innovation, MRC Population Health Research Unit{{Cite web|url=https://www.mrc-phru.ox.ac.uk/research/big-data-and-computing-innovation|title=Big Data and Computing Innovation — Medical Research Council Population Health Research Unit (MRC PHRU)}}
- Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre{{Cite web|url=https://oxfordbrc.nihr.ac.uk/research-themes-overview/clinical-informatics-and-big-data/|title = Clinical Informatics and Big Data}}
- Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust
See also
References
{{Reflist}}
External links
- [https://www.ndph.ox.ac.uk/team/martin-landray Martin Landray — Nuffield Department of Population Health]
- [https://www.bdi.ox.ac.uk/Team/martin-landray Martin Landray — Oxford Big Data Institute]
{{Authority control}}
{{DEFAULTSORT:Landray, Martin}}
Category:Academics of the University of Oxford
Category:British epidemiologists